Yanisa Chuenkasamekul
Rheumatology · Covina, CANPI 1184266678
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 801 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 17.6% — the pattern of someone who eats at a lot of different presentations.
Across 801 payments — averaging $19.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Amgen$2K
- Johnson & Johnson$2K
- UCB, Inc.$1K
- Novartis$1K
- AstraZeneca$1K
- plus $4K from 29 others
What the payments were for
- Food & beverage$15,598100%
- Education$230%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 150 | $2,746 |
| Amgen(2 entities) | 126 | $2,442 |
| Johnson & Johnson | 109 | $2,137 |
| UCB, Inc. | 74 | $1,408 |
| Novartis | 69 | $1,333 |
| AstraZeneca(2 entities) | 64 | $1,300 |
| GSK | 68 | $1,202 |
| Mallinckrodt Hospital Products Inc. | 26 | $548 |
| Lilly USA, LLC | 26 | $485 |
| Aurinia Pharma U.S., Inc. | 14 | $300 |
| Pfizer | 15 | $296 |
| Radius Health, Inc. | 8 | $182 |
| Kiniksa Pharmaceuticals, Ltd. | 3 | $139 |
| E.r. Squibb & Sons, L.L.C. | 5 | $119 |
| Janssen Scientific Affairs, LLC | 1 | $116 |
| Currax Pharmaceuticals LLC | 8 | $113 |
| ANI Pharmaceuticals, Inc. | 5 | $101 |
| Fresenius Kabi USA, LLC | 3 | $78 |
| Cumberland Pharmaceuticals, Inc. | 3 | $67 |
| Boehringer Ingelheim | 2 | $64 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $54 |
| Verona Pharma, Inc. | 2 | $49 |
| Teva Pharmaceuticals USA, Inc. | 2 | $49 |
| Sobi, Inc | 2 | $42 |
| Tonix Medicines, Inc. | 1 | $39 |
| Scilex Pharmaceuticals Inc. | 2 | $35 |
| Sanofi-aventis U.S. LLC | 2 | $31 |
| Hikma Pharmaceuticals USA | 2 | $30 |
| Arbor Pharmaceuticals, Inc. | 1 | $24 |
| Novo Nordisk | 1 | $20 |
| Celltrion USA Inc. | 1 | $16 |
| Ultragenyx Pharmaceutical Inc. | 1 | $16 |
| Merck | 1 | $15 |
| Alvogen Inc | 1 | $14 |
| Octapharma USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,621 in reported general payments places this provider in the 75th percentile of 808 rheumatology providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Diclofenac Sodium | 181 | $19,240 |
| MethotrexateMethotrexate Sodium | 333 | $9,007 |
| Hydroxychloroquine Sulfate | 213 | $8,083 |
| Lidocaine | 117 | $7,627 |
| Pregabalin | 409 | $6,956 |
| Mycophenolate Mofetil | 32 | $4,716 |
| Cevimeline Hcl | 18 | $3,270 |
| Duloxetine Hcl | 103 | $2,396 |
| Baclofen | 187 | $2,198 |
| Gabapentin | 213 | $2,055 |
| Clobetasol Propionate | 29 | $1,383 |
| Sulfasalazine | 40 | $1,241 |
| Leflunomide | 17 | $1,226 |
| Alendronate Sodium | 203 | $1,202 |
| Colchicine | 31 | $912 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Scilex Pharmaceuticals Inc.Colchicine | $35 | $91231 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 808 rheumatology providers in California.
Other rheumatology in Covina
- Samy MetyasCovina$1.3M
- Sudhakar TumuluriSan Francisco$2.8M
- Ara DikranianSan Diego$2.2M
- Orrin TroumSanta Monica$1.8M
- Robin DoreTustin$1.5M
- Rhonda LambertSan Mateo$1.1M
- William ShielMission Viejo$924K
- Mark BoriginiDowney$920K
- Adam KreitenbergTarzana$863K
- Roger KornuTustin$802K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.